Clinical Trials Logo

Acute Radiation Syndrome clinical trials

View clinical trials related to Acute Radiation Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04650555 Completed - Clinical trials for Acute Radiation Syndrome

BIO 300 Oral Powder Safety and Pharmacokinetics

Start date: December 8, 2020
Phase: Phase 1
Study type: Interventional

Open-label, single ascending dose and multiple single dose study in healthy volunteers to evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study consists of a single dose given daily for 6 consecutive days.

NCT ID: NCT03585803 Completed - Clinical trials for Acute Radiation Syndrome

A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011

Start date: June 11, 2018
Phase: Phase 1
Study type: Interventional

This trial is designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic of KMRC011 injection in healthy adult volunteers.

NCT ID: NCT02343133 Completed - Clinical trials for Hematopoietic Syndrome Due to Acute Radiation Syndrome

Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome

Start date: January 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether HemaMax is safe and well tolerated to support efficacy under FDA's Animal Rule to reduce the morbidity and mortality associated with the hematopoietic syndrome of acute radiation syndrome.

NCT ID: NCT01742221 Completed - Clinical trials for Hematopoietic Syndrome Due to Acute Radiation Syndrome

Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

Start date: August 2012
Phase: Phase 1
Study type: Interventional

This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of HemaMax in healthy male and female volunteers.

NCT ID: NCT00504335 Completed - Clinical trials for Acute Radiation Syndrome

Safety and Pharmacokinetic Study of BIO 300 Capsules

Start date: June 2007
Phase: Phase 1
Study type: Interventional

This trial is designed to evaluate the safety and pharmacokinetics of BIO 300 capsules when administered orally to healthy male and female volunteers. BIO 300 is expected to be safe for use starting at 500 mg.